View in EDS HTML Full Text PDF Full Text

A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.

Saved in:
Bibliographic Details
Title: A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
Authors: Fox E; Central Texas Neurology Consultants, Round Rock, TX, USA., Lovett-Racke AE; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Gormley M; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Liu Y; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA., Petracca M; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Cocozza S; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA/Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy., Shubin R; SC3 Research Group, Inc., Pasadena, CA, USA., Wray S; Hope Neurology Multiple Sclerosis Center, Knoxville, TN, USA., Weiss MS; TG Therapeutics, Inc., New York, NY, USA., Bosco JA; TG Therapeutics, Inc., New York, NY, USA., Power SA; TG Therapeutics, Inc., New York, NY, USA., Mok K; TG Therapeutics, Inc., New York, NY, USA., Inglese M; Medical Center, Department of Neurology, Radiology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2021 Mar; Vol. 27 (3), pp. 420-429. Date of Electronic Publication: 2020 Apr 30.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 32351164
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Fox+E%22">Fox E</searchLink>; Central Texas Neurology Consultants, Round Rock, TX, USA.<br /><searchLink fieldCode="AU" term="%22Lovett-Racke+AE%22">Lovett-Racke AE</searchLink>; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Gormley+M%22">Gormley M</searchLink>; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Liu+Y%22">Liu Y</searchLink>; Department of Microbial Infection and Immunity, The Ohio State University Wexner Medical Center, Columbus, OH, USA.<br /><searchLink fieldCode="AU" term="%22Petracca+M%22">Petracca M</searchLink>; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Cocozza+S%22">Cocozza S</searchLink>; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA/Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy.<br /><searchLink fieldCode="AU" term="%22Shubin+R%22">Shubin R</searchLink>; SC3 Research Group, Inc., Pasadena, CA, USA.<br /><searchLink fieldCode="AU" term="%22Wray+S%22">Wray S</searchLink>; Hope Neurology Multiple Sclerosis Center, Knoxville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Weiss+MS%22">Weiss MS</searchLink>; TG Therapeutics, Inc., New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Bosco+JA%22">Bosco JA</searchLink>; TG Therapeutics, Inc., New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Power+SA%22">Power SA</searchLink>; TG Therapeutics, Inc., New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Mok+K%22">Mok K</searchLink>; TG Therapeutics, Inc., New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Inglese+M%22">Inglese M</searchLink>; Medical Center, Department of Neurology, Radiology and Neuroscience, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229509185%22">Multiple sclerosis (Houndmills, Basingstoke, England)</searchLink> [Mult Scler] 2021 Mar; Vol. 27 (3), pp. 420-429. <i>Date of Electronic Publication: </i>2020 Apr 30.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22SAGE+Publications%22">SAGE Publications </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9509185 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1477-0970 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2213524585%22">13524585 </searchLink><i>NLM ISO Abbreviation: </i>Mult Scler <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=32351164
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1177/1352458520918375
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 420
    Titles:
      – TitleFull: A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Fox E
      – PersonEntity:
          Name:
            NameFull: Lovett-Racke AE
      – PersonEntity:
          Name:
            NameFull: Gormley M
      – PersonEntity:
          Name:
            NameFull: Liu Y
      – PersonEntity:
          Name:
            NameFull: Petracca M
      – PersonEntity:
          Name:
            NameFull: Cocozza S
      – PersonEntity:
          Name:
            NameFull: Shubin R
      – PersonEntity:
          Name:
            NameFull: Wray S
      – PersonEntity:
          Name:
            NameFull: Weiss MS
      – PersonEntity:
          Name:
            NameFull: Bosco JA
      – PersonEntity:
          Name:
            NameFull: Power SA
      – PersonEntity:
          Name:
            NameFull: Mok K
      – PersonEntity:
          Name:
            NameFull: Inglese M
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2021 Mar
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-electronic
              Value: 1477-0970
          Numbering:
            – Type: volume
              Value: 27
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Multiple sclerosis (Houndmills, Basingstoke, England)
              Type: main
ResultId 1